These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 24479749)

  • 1. T-type Ca channel blockers in patients with chronic kidney disease in clinical practice.
    Abe M; Okada K; Soma M
    Curr Hypertens Rev; 2013 Aug; 9(3):202-9. PubMed ID: 24479749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ca2+ channel subtypes and pharmacology in the kidney.
    Hayashi K; Wakino S; Sugano N; Ozawa Y; Homma K; Saruta T
    Circ Res; 2007 Feb; 100(3):342-53. PubMed ID: 17307972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling.
    Moore KH; Clemmer JS
    Am J Physiol Renal Physiol; 2021 Oct; 321(4):F548-F557. PubMed ID: 34486399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-/N-type calcium channel blockers and proteinuria.
    Ando K
    Curr Hypertens Rev; 2013 Aug; 9(3):210-8. PubMed ID: 24479751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotective effects of the L-/T-type calcium channel blocker benidipine in patients with hypertension.
    Tomino Y
    Curr Hypertens Rev; 2013 May; 9(2):108-14. PubMed ID: 23971692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-type Ca channel blockade as a determinant of kidney protection.
    Hayashi K; Homma K; Wakino S; Tokuyama H; Sugano N; Saruta T; Itoh H
    Keio J Med; 2010; 59(3):84-95. PubMed ID: 20881449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal microcirculation and calcium channel subtypes.
    Homma K; Hayashi K; Yamaguchi S; Fujishima S; Hori S; Itoh H
    Curr Hypertens Rev; 2013 Aug; 9(3):182-6. PubMed ID: 24479750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.
    Zhao HJ; Li Y; Liu SM; Sun XG; Li M; Hao Y; Cui LQ; Wang AH
    Ren Fail; 2016 Jul; 38(6):849-56. PubMed ID: 27055479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidney disease.
    Omae K; Ogawa T; Nitta K
    Heart Vessels; 2009 Jul; 24(4):301-7. PubMed ID: 19626404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study.
    Fu EL; Clase CM; Evans M; Lindholm B; Rotmans JI; Dekker FW; van Diepen M; Carrero JJ
    Am J Kidney Dis; 2021 May; 77(5):719-729.e1. PubMed ID: 33246024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of N- and T-type calcium channel blocker on proteinuria, blood pressure and kidney function in hypertensive patients: a meta-analysis.
    Thamcharoen N; Susantitaphong P; Wongrakpanich S; Chongsathidkiet P; Tantrachoti P; Pitukweerakul S; Avihingsanon Y; Praditpornsilpa K; Jaber BL; Eiam-Ong S
    Hypertens Res; 2015 Dec; 38(12):847-55. PubMed ID: 26134125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease.
    Abe M; Okada K; Maruyama N; Matsumoto S; Maruyama T; Fujita T; Matsumoto K; Soma M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1027-37. PubMed ID: 20649501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of T-type selective calcium antagonist on renal microcirculation: studies in the isolated perfused hydronephrotic kidney.
    Ozawa Y; Hayashi K; Nagahama T; Fujiwara K; Saruta T
    Hypertension; 2001 Sep; 38(3):343-7. PubMed ID: 11566902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
    Huang RS; Cheng YM; Zeng XX; Kim S; Fu P
    Chin Med J (Engl); 2016 Mar; 129(5):562-9. PubMed ID: 26904991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of T-type calcium channel blockers on renal function and aldosterone in patients with hypertension: a systematic review and meta-analysis.
    Li X; Yang MS
    PLoS One; 2014; 9(10):e109834. PubMed ID: 25330103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation.
    Hayashi K; Wakino S; Homma K; Sugano N; Saruta T
    J Pharmacol Sci; 2005 Nov; 99(3):221-7. PubMed ID: 16293936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease.
    Fujita T; Ando K; Nishimura H; Ideura T; Yasuda G; Isshiki M; Takahashi K;
    Kidney Int; 2007 Dec; 72(12):1543-9. PubMed ID: 17943080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential risks of calcium channel blockers in chronic kidney disease.
    Griffin KA; Bidani AK
    Curr Cardiol Rep; 2008 Nov; 10(6):448-55. PubMed ID: 18950553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium channels blockers and progression of kidney disease.
    Ziakka S; Kaperonis N; Ferentinou E; Karakasis F; Ntatsis G; Kourvelou C; Papagalanis N
    Ren Fail; 2007; 29(8):1003-12. PubMed ID: 18067048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.